Multiplex assays market to reach $8.84 billion by 2035, SNS says

The global multiplex assays market is projected to expand to USD 8.84 billion by 2035 from USD 3.31 billion in 2025, according to SNS Insider, implying a 10.70% CAGR over 2026–2035. The report ties the outlook to rising demand for high-throughput, lower-cost diagnostic tools, broader use of multiplex assays in clinical diagnostics and molecular diagnostics, and growing applications in drug discovery, biomarker research and precision medicine. It also cites the increasing burden of chronic and infectious diseases and continued adoption of multiplex PCR and flow cytometry across hospitals, clinical laboratories and research institutes. Throughput capacity for multiplex assays is projected to exceed 84.24 million units per year in 2025. Reagents and consumables held the largest product share in 2025 at 71.25%, while software and services are forecast to grow fastest at an 8.40% CAGR. Protein-based multiplex assays led by type with a 52.35% share, while nucleic acid-based assays are expected to grow fastest at an 8.50% CAGR. Flow cytometry accounted for the largest technology share at 34.41%, and multiplex PCR/real-time PCR is projected to post the fastest growth at a 9.41% CAGR. Research and development was the largest application segment with a 55.12% share, while clinical diagnostics is expected to expand fastest at a 13.64% CAGR. Pharmaceutical and biotechnology companies led end-user demand with a 37.14% share, and clinical laboratories are projected to grow fastest at an 11.21% CAGR. North America held a 38.45% market share in 2025, while Asia Pacific is expected to record the fastest growth at a 13.15% CAGR. SNS Insider valued the U.S. market at USD 1.12 billion in 2025 and projected it to reach USD 2.65 billion by 2035 at a 9.36% CAGR.